Amicus Therapeutics (FOLD) Stock Price, Quote & News

Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 662 2000

Fax: 609 662 2001

Website: amicusrx.com

Address:

47 Hulfish Street, Princeton, United States

HateTradingStocks Oct. 4 at 10:58 PM

$FOLD I hate babies. I hate the way they smile and giggle. My ex-girlfriend used to smile and giggle like that. Someone ran her over in a terrible car accident. I feel bad for her now. She can’t walk and doesn’t smile or giggle anymore. Sometimes she poops herself. I broke up with her once that happened.

0 · Reply

Doozio Oct. 4 at 10:27 PM

Go ahead 🐑. They told yo to $FOLD in 2021 n FBRXetabout. All da 🐑 been SPOT and yo estimate it’s 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 4 at 10:18 PM

MAMA said don’t $FOLD da huckleberries are coming while da 🐑 went to cash n it’s 3wt during 🐒🍌🧠⏰♾️

0 · Reply

TeeMan123 Oct. 3 at 9:26 PM

$FOLD the trial ended on Tuesday… nothing really notable posted on legal site, some anecdotes from folks in the room the judge sounded much more so on FOLD side, could take the judge several months to issue verdict though, maybe a deal is made before hand

1 · Reply

Hognose Oct. 3 at 2:48 PM

$TEM $DT $FOLD ready to rip. Uipath $PATH isnt looking too bad either.

0 · Reply

shakky Oct. 1 at 8:04 PM

$FOLD sell off on very high volume.Did some news come out?

2 · Reply

CaptainAmrica Oct. 1 at 2:15 PM

$FOLD.... Long...In the midst of a real breakout...

1 · Reply

highnihilism Sep. 30 at 12:54 PM

$TALO Talos Energy: 48 trades, $13.5K vs $14K avg (0.95x). $12.8K calls / $0.7K puts. $XRAY Dentsply Sirona: 50 trades, $15.6K vs $36K avg (0.44x). $12.7K calls / $2.9K puts. $FOLD Amicus Therapeutics: 28 trades, $25.7K vs $37K avg (0.69x). $12.7K calls / $13K puts. $ALMS Alumis: 26 trades, $14.5K vs $17K avg (0.86x). $12.7K calls / $1.8K puts.

0 · Reply

Mikelonggggggggg Sep. 29 at 2:48 PM

$FOLD DAMNIT why didn't you guy's settle!!!!???

0 · Reply

TeeMan123 Sep. 26 at 1:08 PM

$FOLD party's updated the court docket last night indicated they have failed to settle despite email and phone communication, they tell the court they continue to engage but as of now trial commences Monday.......

1 · Reply

3 Of My Favorite Biotech Stocks Under $10

DVAX MRNA NUVB PFE

Sep 9, 2025, 6:06 PM EDT - 25 days ago

Amicus Therapeutics, Inc. (FOLD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 9:00 AM EDT - 26 days ago

New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM

Aug 29, 2025, 9:06 PM EDT - 5 weeks ago

In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful

Aug 29, 2025, 7:00 AM EDT - 5 weeks ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025

Aug 25, 2025, 4:22 PM EDT - 5 weeks ago

Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student

Aug 21, 2025, 6:20 PM EDT - 6 weeks ago

In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump

Aug 18, 2025, 2:47 PM EDT - 6 weeks ago

The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination

Aug 1, 2025, 4:04 PM EDT - 2 months ago

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Jul 31, 2025, 3:12 PM EDT - 2 months ago

Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 7:00 AM EDT - 2 months ago

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

Jul 28, 2025, 6:20 PM EDT - 2 months ago

In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data

Jul 21, 2025, 7:00 AM EDT - 2 months ago

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jul 10, 2025, 8:00 AM EDT - 3 months ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

Jun 25, 2025, 7:00 AM EDT - 3 months ago

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

Jun 20, 2025, 5:03 PM EDT - 3 months ago

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

Jun 16, 2025, 2:02 PM EDT - 3 months ago

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

Jun 13, 2025, 6:23 PM EDT - 4 months ago

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

Jun 12, 2025, 4:16 PM EDT - 4 months ago

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Jun 12, 2025, 10:14 AM EDT - 4 months ago

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Jun 3, 2025, 7:00 AM EDT - 4 months ago

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

May 30, 2025, 7:00 AM EDT - 4 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

May 7, 2025, 7:00 AM EDT - 5 months ago

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

May 1, 2025, 4:24 PM EDT - 5 months ago

Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 5 months ago

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

Apr 30, 2025, 7:12 PM EDT - 5 months ago

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Apr 21, 2025, 7:00 AM EDT - 5 months ago

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

Mar 17, 2025, 10:21 AM EDT - 7 months ago

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

Mar 6, 2025, 4:31 PM EST - 7 months ago

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer

Mar 3, 2025, 2:04 PM EST - 7 months ago

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act

Feb 27, 2025, 7:00 AM EST - 7 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

Feb 19, 2025, 2:04 PM EST - 8 months ago

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:00 AM EST - 8 months ago

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

Feb 17, 2025, 5:59 PM EST - 8 months ago

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm

Feb 10, 2025, 7:00 AM EST - 8 months ago

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

Feb 3, 2025, 7:00 AM EST - 8 months ago

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025

Jan 23, 2025, 3:38 PM EST - 9 months ago

NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases

Jan 13, 2025, 1:46 PM EST - 9 months ago

NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined

Jan 13, 2025, 12:56 PM EST - 9 months ago

3 Oversold Biotech Names

AVDL JAZZ VKTX XBI

Jan 12, 2025, 4:00 PM EST - 9 months ago

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Jan 2, 2025, 7:00 AM EST - 9 months ago

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 8:30 AM EST - 9 months ago

Fold, Inc. Announces Up To $30 Million Convertible Note Financing Backed by Bitcoin

Dec 27, 2024, 1:33 PM EST - 10 months ago

Amicus Therapeutics: Cheap Heading Into 2025

Dec 23, 2024, 3:43 PM EST - 10 months ago

NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It

Dec 18, 2024, 1:09 PM EST - 10 months ago

NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act

Dec 13, 2024, 3:28 PM EST - 10 months ago

Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension

Dec 13, 2024, 2:10 PM EST - 10 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

IMRX

Dec 3, 2024, 1:14 PM EST - 10 months ago

NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial

HateTradingStocks Oct. 4 at 10:58 PM

0 · Reply

Doozio Oct. 4 at 10:27 PM

Go ahead 🐑. They told yo to $FOLD in 2021 n FBRXetabout. All da 🐑 been SPOT and yo estimate it’s 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 4 at 10:18 PM

MAMA said don’t $FOLD da huckleberries are coming while da 🐑 went to cash n it’s 3wt during 🐒🍌🧠⏰♾️

0 · Reply

TeeMan123 Oct. 3 at 9:26 PM

1 · Reply

Hognose Oct. 3 at 2:48 PM

$TEM $DT $FOLD ready to rip. Uipath $PATH isnt looking too bad either.

0 · Reply

shakky Oct. 1 at 8:04 PM

$FOLD sell off on very high volume.Did some news come out?

2 · Reply

CaptainAmrica Oct. 1 at 2:15 PM

$FOLD.... Long...In the midst of a real breakout...

1 · Reply

highnihilism Sep. 30 at 12:54 PM

0 · Reply

Mikelonggggggggg Sep. 29 at 2:48 PM

$FOLD DAMNIT why didn't you guy's settle!!!!???

0 · Reply

TeeMan123 Sep. 26 at 1:08 PM

1 · Reply

Mikelonggggggggg Sep. 25 at 5:18 PM

$FOLD Can we get a lawsuit settlement announcement ?

1 · Reply

ZacksResearch Sep. 25 at 4:38 PM

$RIGL vs. $FOLD — which biotech has the bigger upside in 2025? Both are pushing rare disease therapies, with rising sales from key drugs setting up solid growth prospects. Full growth potential breakdown here 👉 https://www.zacks.com/stock/news/2757153/rigl-vs-fold-which-biotech-stock-offers-better-growth-potential?cid=sm-stocktwits-2-2757153-teaser-14160&ADID=SYND_STOCKTWITS_TWEET_2_2757153_TEASER_14160

0 · Reply

ZacksResearch Sep. 25 at 3:38 PM

$RIGL vs. $FOLD: Why Rigel is the Clear Winner 🚀 RIGL’s sales are expected to increase around 57% in 2025, fueled by strong Tavalisse performance and its growing portfolio. With an 80.1% YTD rally, this Zacks Rank #1 stock is a standout against FOLD’s 11.3% decline. Discover the full investment case here 👉 https://www.zacks.com/stock/news/2757153/rigl-vs-fold-which-biotech-stock-offers-better-growth-potential?cid=sm-stocktwits-2-2757153-body-14151&ADID=SYND_STOCKTWITS_TWEET_2_2757153_BODY_14151

0 · Reply

AGProfitOptions Sep. 21 at 7:33 PM

$FOLD Bad week for this one. For those expecting a cash out on the Friday high, look elsewhere 📉📉📉

0 · Reply

BrandonBushby1007 Sep. 21 at 2:54 PM

$FOLD Biopharmaceutical growth. Breaking above consolidation. Volume expansion noted. Relative strength.

0 · Reply

Doozio Sep. 19 at 4:28 AM

Well they bought out OLO like MYOK out of 🐑⏰♾️ as all the 🐑 been SPOT so who is gonna $FOLD 🐒🍌🧠⏰♾️?

0 · Reply

RunnerSignals Sep. 18 at 10:33 PM

Upgrade party continues! $ACB $WYNN $FOLD $HSAI $MBLY catching analyst attention today https://stocksrunner.com/news/2025-09-18-top-stock-upgrades-today-drive-market-action-across-sectors

0 · Reply

stockstelegraph Sep. 18 at 2:58 PM

Top Analyst Upgrades Today 🚀 💠 $WDAY: 285 ➜ Buy 💠 $NKE: 76 ➜ 90 💠 $FOLD: Hold ➜ Buy 💠 $CSX: 37 ➜ 39 💠 $AVAH: 6 ➜ 10 🧠 Dive deeper: 👉 stockstelegraph.com/upgrades-downgrades #stocks #upgrades #premarket #investing #stockmarket

0 · Reply

G101SPM Sep. 18 at 12:00 PM

$FOLD $8.45 ask. BUY/NEW LONG POSITION carries SPM 86.92 tag to $12.00 (1st level).

0 · Reply

notreload_ai Sep. 18 at 11:37 AM

Analysts Needham ($14 PT) & Morgan Stanley ($12 PT) are bullish on $FOLD. Its DMX-200 drug for FSGS is de-risked by FDA changes, has huge sales potential ($1.5B+), and isn't yet priced into the stock. Both firms issued "Buy" ratings! https://notreload.xyz/amicus-therapeutics-analysts-are-bullish/

0 · Reply

JarvisFlow Sep. 18 at 10:00 AM

Needham updates rating for Amicus Therapeutics ( $FOLD ) to Buy, target set at 14.

0 · Reply

Estimize Sep. 17 at 1:00 PM

Wall St is expecting 0.03 EPS for $FOLD Q3 [Reporting 11/05 BMO] http://www.estimize.com/intro/fold?chart=historical&metric_name=eps&utm_co

0 · Reply

Market Cap	2.53B
Revenue (ttm)	528.30M
Net Income (ttm)	-56.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	294.64
Profit Margin	-10.62%
Debt to Equity Ratio	1.92

Volume	6,600,200
Avg Vol	4,924,190
Day's Range	N/A - N/A
Shares Out	308.24M
Stochastic %K	52%
Beta	0.56
Analysts	Strong Sell
Price Target	$15.92